By Elric Langton | 6th December 2021
Poolbeg Pharma (AIM: POLB), a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for Melioidosis, as well as evaluate five other infectious disease portfolio assets through the University College Dublin ('UCD') andβ¦